Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure

Angiology. 2014 Jul;65(6):533-7. doi: 10.1177/0003319713489340. Epub 2013 May 13.

Abstract

It is unclear whether carvedilol and nebivolol will produce different effects on platelet function and prothrombotic state in heart failure (HF). Thus, we compared their effects on these functions in patients with nonischemic HF. We included 61 patients with symptomatic nonischemic HF having ejection fraction ≤40%. The patients were randomized to carvedilol (n = 31) or nebivolol (n = 30). Analyses were made at baseline, 3, and 6 months. At 6 months, mean platelet volume (MPV) was significantly lowered by both carvedilol and nebivolol therapy. However, MPV tended to be lower in the carvedilol group (7.7 ± 1.0 vs 8.0 ± 0.7 fL, P = .05). Fibrinogen and d-dimer levels were significantly decreased in but comparable in both the groups. Carvedilol and nebivolol have similar beneficial effects on platelet function and prothrombotic state in patients with nonischemic HF.

Keywords: d-dimer; carvedilol; fibrinogen; heart failure; mean platelet volume; nebivolol.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adrenergic beta-1 Receptor Antagonists / therapeutic use*
  • Benzopyrans / therapeutic use*
  • Carbazoles / therapeutic use*
  • Carvedilol
  • Drug Therapy, Combination
  • Ethanolamines / therapeutic use*
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinogen / analysis
  • Heart Failure / blood
  • Heart Failure / drug therapy*
  • Humans
  • Male
  • Mean Platelet Volume
  • Middle Aged
  • Nebivolol
  • Propanolamines / therapeutic use*
  • Single-Blind Method

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • Benzopyrans
  • Carbazoles
  • Ethanolamines
  • Fibrin Fibrinogen Degradation Products
  • Propanolamines
  • fibrin fragment D
  • Nebivolol
  • Carvedilol
  • Fibrinogen